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Sensitization to fungi and long term or uncontrolled fungal infection are associated with poor control of asthma,
the likelihood of more severe disease and complications such as bronchiectasis and chronic pulmonary
aspergillosis. Modelling suggests that >6.5 million people have severe asthma with fungal sensitizations (SAFS), up
to 50% of adult asthmatics attending secondary care have fungal sensitization, and an estimated 4.8 million adults
have allergic bronchopulmonary aspergillosis (ABPA). There is much uncertainty about which fungi and fungal
allergens are relevant to asthma, the natural history of sensitisation to fungi, if there is an exposure response
relationship for fungal allergy, and the pathogenesis and frequency of exacerbations and complications. Genetic
associations have been described but only weakly linked to phenotypes. The evidence base for most management
strategies in ABPA, SAFS and related conditions is weak. Yet straightforward clinical practice guidelines for
management are required. The role of environmental monitoring and optimal means of controlling disease to
prevent disability and complications are not yet clear. In this paper we set out the key evidence supporting the role
of fungal exposure, sensitisation and infection in asthmatics, what is understood about pathogenesis and natural
history and identify the numerous areas for research studies.
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Fungal exposure is a daily fact of human existence, which
infrequently results in disease. Yet fungal allergy drives
asthma severity in very large numbers of people affected by
severe asthma. Available statements from different medical
associations are unequivocal in declaring that fungi are sen-
sitizers and exacerbate allergic asthma (American College
of Occupational and Environmental Medicine [1], Institute
of Medicine, American Academy of Allergy, Asthma and
Clinical Immunology [2] and American College of Medical
Toxicology). Increasing rates of fungi-associated occupa-
tional asthma are also of concern. In contrast to allergy to
other environmental agents, antifungal therapy is available,
yet our knowledge of who, when and how to treat is in its* Correspondence: ddenning@manchester.ac.uk
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unless otherwise stated.infancy. As with other allergens, immunization could be
helpful but has barely been addressed.
The European Academy of Allergy and Clinical Im-
munology (EAACI) Asthma Section decided to address
this deficiency by forming a Task Force to address ‘Fun-
gal Allergy in Asthma’. The first product of the Task
Force is a summary of what is and what is not known
about this topic, written from the perspective of the pro-
gressive practicing clinician. It is focused on the lower
respiratory tract, does not address cystic fibrosis (CF) in
any depth and highlights research needs in the area.
Other consensus reviews and statements relevant to this
topic have described the status of allergic bronchopul-
monary aspergillosis (ABPA) in cystic fibrosis [3], lower
airways interaction with fungi and its clinical conse-
quences [4] and the whole topic of ABPA [5], the last
with recommendations for a new definition of ABPA.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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While fungal exposure is universal, sensitisation and dis-
ease are not. Very early life airborne contact with fungi
is well demonstrated by studies with Pneumocystis ser-
ology and pneumonia in healthy children and those with
cancer [6]. Broadly speaking, fungi can cause problems
to the lung in two ways; either by acting as aeroallergens
or as a pathogen causing infection. Some fungi can do
both, often simultaneously. To cause infection in the
lung the fungus has to be able to grow at body
temperature and this property is restricted to a relatively
narrow range of fungi, particularly yeasts and members
of the Aspergillus and Penicillium genera. The common-
est fungus causing lung infections is Aspergillus fumiga-
tus, although other Aspergillus spp. are also implicated
[7]. Fungal allergens, which can cause rhinitis and
asthma, but rarely cause infection, include spores from
the plant pathogens Cladosporium and Alternaria spp.
A third potential cause of ill-health from fungi are vola-
tile organic compounds and mycotoxins released by
moulds such as Stachybotrys spp, which remains contro-
versial and will not be discussed here in depth.
Sensitisation and allergy
Allergy is an inflammatory response caused by an envir-
onmentally delivered and often non-pathogenic agent
and is caused by an exaggerated immune response rather
than the pathogenic, pharmacological or toxic properties
of the primary agent. As fungi are complex eukaryotes,
all forms of allergic immune response [8] should be con-
sidered as potentially leading to fungal allergy, although
the most well-recognised clinical responses, such as
asthma and rhinitis caused by Alternaria alternata, are
mediated in a straightforward immunoglobulin (Ig) E/
TH2 manner. The stipulation on including evidence of
an inflammatory response in the definition of allergic
disease is to distinguish allergy from sensitisation. Many
people with elevated specific serum (s)IgE (or for that
matter other intermediates of immune response) against
a certain agent (sensitisation) do not develop symptoms
when exposed to that agent. However, this is not a fixed
difference as sensitisation can evelove into allergy de-
pending on the level of exposure, co-factors present at
the time of exposure and the age of person, with periods
in their life when they develop symptoms and periods
when they have sub-clinical disease or are in complete
remission induced by immune tolerance.
Infection
Viable microorganisms including fungi can have a range
of interactions with their human host. Infection refers to
the presence of a microorganism, which leads directly to
ill-health as a result of its pathogenic properties. Colon-
isation refers to any situation where a microorganismbecomes established in a new environment and doesn’t
imply any particular relationship between the organism
and the host. Both pathogenic and non-pathogenic or-
ganisms can act as commensals. The ability of microor-
ganisms cause disease depends on their pathogenic
potential, the number of organisms, the integrity of host
defense, the strain of the organism and no doubt other
factors, which are yet to be defined. If there is evidence
of tissue dysfunction which is likely to be due to the
presence of the microorganism then the term infection is
preferable to colonisation.
Fungi can cause a number of different types of infec-
tion, separately from their ability to act as sensitisers.
Contrasting patterns of fungi-host interactions are illus-
trated in Figure 1, with A. fumigatus remarkable as it
can cause invasive infection in the immunocomprom-
ised, chronic pulmonary aspergillosis and Aspergillus
bronchitis in non-immunocompromised individuals with
underlying lung damage, and allergic disease of the
upper and lower airways. In contrast, Pneumocystis is a
pathogen of the immunocompromised, but not an aller-
genic fungus or sensitizer, which greatly differs from the
primary skin pathogen Trichopyton interdigitale (and other
species) which causes cutaneous infection in hundreds of
millions of people, cannot grow in the lung, but is a com-
mon sensitising fungus associated with severe asthma.
Asthma
This position paper concerns fungal allergy in asthma.
However asthma itself is not a straightforward term and
requires clarification. Asthma can be defined in two
ways, descriptively and rather loosely as a multifactorial
chronic inflammatory disease of the airways with an as-
sociated set of typical symptoms and evidence of variable
airflow obstruction, or more strictly as a physiological ab-
normality in which there is documented rapid changes in
the resistance to airflow and increased sensitivity of the
airway smooth muscle to bronchoconstricting stimuli (air-
way hyperresponsiveness (AHR)) [10]. Bio-statistical ap-
proaches to measuring heterogeneity in asthma have
suggested that asthma as broadly defined is comprised of
a number of distinct endotypes, not all of which have ob-
vious AHR or variable airflow obstruction [11,12], and im-
provement in symptoms of asthma are not always
reflected in better physiological measurement of airflow.
Many conditions can mimic asthma, or occur alongside it,
confusing the clinical picture.
Current disease concepts, definitions and terminology
We have tabulated the current and proposed definitions
of fungal allergy, sensitisation and related conditions in
Table 1. ABPA was first described in 1952 [13], and the
criteria for diagnosis were defined during the 1970s and
1980s [14-17]. It is recognised that occasionally ABPA
Figure 1 Patterns of fungal interactions with humans, illustrating different host pathogen interactions, based on the host damage
response framework [9].
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Table 1 Definitions
Entity Current definition Proposed definition Comments
Fungal allergy Immune-mediated inflammatory response to a
fungus sometimes leading to tissue damage
Same, being inclusive of all
allergic immunopathologies
Demonstrating and documenting ‘Tissue
damage’ can sometimes be difficult.
Fungal sensitisation Immune-mediated response to a fungus, without
evidence of inflammation or tissue damage,
usually documented by an elevated
fungal-specific IgE.
Same Tends to reflect specific-IgE response
(or skin prick test result) only.
Fungal colonisation None 1. One (or preferably two or
more) respiratory sample (s)
positive for a fungus by
culture or PCR
Such criteria may apply to other
filamentous fungi, but not Candida. They
need to be tested in prospective studies.
2. No new major respiratory
symptoms
3. No evidence of ABPA or other
forms of aspergillosis
4. No overt immunocompromise
5. Negative fungal specific
IgG in serum.
ABPA 1. Asthma (or CF) with deterioration
of lung function
1. Asthma (or CF) No definition addressed robustly with
prospective study and combinations
of diagnostic criteria.
2. Elevated total serum IgE
of >1000 ng/ml (>417 IU/ml)
2. A. fumigatus skin test positive
or elevated A. fumigatus IgE
levels
3. Elevated A. fumigatus specific
IgE and/or IgG antibodies
3. Elevated total serum
IgE of >1000 IU/ml
+ 2 of the following:




c. Eosinophil count >500
cells/uL
4. Immediate Aspergillus species
skin test reactivity
5. Eosinophilia (>1,000/uL)
6. Presence of central
(or proximal) bronchiectasis
7. Chest radiographic infiltrates




1. Asthma (or CF) with deterioration
of lung function
No new proposal, but similar to
ABPA, with substitution of a
different fungal specific tests.
Too rare to develop patient cohorts
to formally validate a definition.
2. Elevated total serum IgE
of >1000 ng/ml (>417 IU/ml)
3. Elevated fungal specific IgE
and/or IgG antibodies
4. Immediate fungal species skin test reactivity
5. Eosinophilia (>1,000/uL)
6. Presence of central
(or proximal) bronchiectasis




1. Severe asthma Severe asthma is a variable,
usually treatment-based entity.
2. Total IgE <1,000 IU/mL
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Table 1 Definitions (Continued)
Variable performance of different skin
and sIgE test reagents, makes SAFS an
imprecise entity until diagnostics improve.
3. Sensitisation to any fungus
by skin prick test or sIgE
Aspergillus
bronchitis
None 1. Multiple respiratory sample
positive for Aspergillus spp by
culture or PCR
Few patients reported. Some cases are
caused by non-fumigatus species, and so
serology criterion may be falsely negative.
2. Major respiratory symptoms
for >4 weeks




5. Positive Aspergillus IgG
or precipitins in serum.
Fungal allergy, fungal sensitisation and fungal colonisation may be clinically silent.
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criteria positive. The cutoff for total serum IgE has not
been rigorously addressed in asthma, although in CF in
the UK a cutoff of >180 IU/mL was 91% sensitive and
90% specific [18] in contrast to an Indian cohort of asth-
matic patients with ABPA in whom a total serum IgE of
2346 IU/mL (sensitivity 87.5%, specificity 66.9%) ap-
peared optimal [5]. The utility of the Patterson criteria
have been prospectively evaluated and compared with
recently introduced criteria by Agarwal [19]. Use of 6
(but not 5, 7 or 8) ‘Patterson criteria’ performed best in
a cohort of 372 asthmatics in northern India [19]; 98%
of the 56 patients with ABPA identified in this study had
bronchiectasis, potentially affecting the performance of
the definition. In addition, some clinicians use expector-
ation of brown coloured mucus plugs as a minor diag-
nostic criteria for ABPA [20], observed in 31 to 69% of
patients [5]. These results raise questions about the opti-
mal disease model and as a consequence the diagnostic
criteria for ABPA (see Figure 2).
There are some other difficulties with current diagnostic
criteria. One of these is overlapping syndromes: separation
of ABPA from Hyper IgE Syndrome (Job’s syndrome) [21],
separation of ABPA complicated by bronchiectasis and
Aspergillus bronchitis [22], separation of ABPA from
chronic pulmonary aspergillosis with a prominent TH2 re-
sponse, including raised serum total and sIgE [23], and
Churg-Strauss syndrome in the absence of biopsy as com-
mon examples. While the presence of central (or prox-
imal) bronchiectasis and/or chest radiographic infiltrates
are usually cited as primary criteria of ABPA [4,24], a re-
cent consensus group suggested that bronchiectasis
should be regarded as a complication of ABPA and avoid-
able may be with earlier therapy [5].
It has been recognised that other fungi can induce a
disease process similar to ABPA, normally called allergicbronchopulmonary mycosis (ABPM) [25]. Many differ-
ent fungi can be implicated and the remarkable feature
in all is a very high total and specific serum IgE to one
or more non-Aspergillus fungi, and other findings usu-
ally found in ABPA. Candida albicans is the most com-
monly reported associated fungus with Bipolaris species,
Schizophyllum commune and Curvularia species the
next most common.
In 2006, the term severe asthma with fungal sensitisa-
tion (SAFS) was introduced [26] and subsequently
shown to be responsive to antifungal therapy [27]. For
consistency, the definition of severe asthma should be
uniform, but is often not fully distinguished from dys-
functional breathing and tracheomalacia. In addition,
current definitions of severe asthma generally reflect
treatment intensity; the WHO identified 3 patterns: 1)
untreated severe asthma, due to undiagnosed asthma or
unavailability of therapy, 2) difficult-to-treat severe
asthma (due to adherence issues, inappropriate or
incorrect use of medicines, environmental triggers
or co-morbidity), and 3) treatment-resistant severe
asthma, including asthma for which control is not
achieved despite the highest level of recommended treat-
ment or asthma which is controlled only with the high-
est level of recommended treatment [28]. Asthma
severity may also change with antifungal therapy, which
was vividly illustrated by a report of antifungal therapy
allowing one third of patients having their asthma sever-
ity downgraded [29]. The definition of SAFS includes
people sensitized to purely allergenic fungi such as Alter-
naria alternata but sensitisation to thermotolerant fungi
is not restricted to people with severe asthma, nor indeed
to people with asthma, creating uncertainty with respect
to the best disease model. Sensitization to A. fumigatus is
more common in severe asthma but it is not uncommon
to find patients who present with severe fixed airflow
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Figure 2 Two contrasting disease models (A and B), with common elements of risk and exposure, but different outcomes. Model A
illustrates a linear relationship between disease and complications, whereas model B provides independent consequences of fungal exposure,
which may or may not be associated. In both models, it is proposed that airway colonization/infection with fungus, and possibly fungal
impaction from breathing airborne non-pathogenic fungi, and/or bacterial infection, continue to drive the inflammatory process.
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ate asthma who are sensitized to A. fumigatus, suggesting
the tissue damage associated with allergy to A. fumigatus
is not restricted to severe disease. While ABPA was ac-
cepted as an endotype of asthma by another EAACI Task
Force [12], SAFS was not and remains a pragmatic defin-
ition to enable an antifungal therapy trial. This issue needs
resolution, possibly by genotyping patients with different
forms of asthma [30], if genotypes allow such classifica-
tions, which they may not.
Fungal sensitisation is also found in allergic rhinosinusi-
tis, without asthma or ABPA, and is a diagnostic criterion
for allergic Aspergillus rhinosinusitis [31,32]. Recently over
10% of patients with chronic obstructive airways disease
(COPD) were found to be sensitized to A. fumigatus and
this was associated with worse pulmonary function [33].
The role of airway colonization or infection by fungi,
is probably significant, and is most notably related to A.
fumigatus. About 60% of asthmatics sensitised to A.
fumigatus have A. fumigatus growing in their sputum on
a single sample (compared to ~5% of normal subjects)
and this increases to 80% if multiple samples are ob-
tained over time (AJW/CHP personal observation). Im-
portantly, these patients have impaired lung function
and increased rates of bronchiectasis compared to
matched controls suggesting evidence of tissue damage[24]. Likewise those asthmatics sensitised to A. fumiga-
tus have a much higher rate of bronchiectasis [34], and
children sensitised to Alternaria are more likely to have
persistent asthma in adulthood [35]. Our supposition is
that fungal airway infection induces an ongoing allergic
stimulus, as although most fungal conidia (spores) re-
lease some allergen(s), many more are produced after
spore swelling and germination [36]; before germination
the conidia are covered in hydrophobin proteins, which
elicit no immune reaction [37]. Preformed allergen from
hyphal fragments may elicit an immune response, even
in the absence of local germination and growth [38],
possibly explaining why increased environmental expos-
ure to Cladosporium spp. or Alternaria alternata, for
example are associated with worse asthma.
Another clinical entity, widely acknowledged in several
southern countries, is “Tricophyton Asthma”. There are
multiple lines of evidence for sensitisation to Tricophy-
ton proteins in asthma patients [39-42], where inhalation
and/or dermal absorption of Trichophyton antigens are
currently considered as possible routes of exposure
[39,41]. Another study showed a high positive skin test
rate in asthmatic patients with Trichophyton infection,
confirming that the presence of cutaneous fungal infec-
tion is a crucial determinant of sensitivity to Trichophy-
ton [42], regardless of the patients’ atopic status [41]. A
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chophyton doubles to 32.4% with increasing severity of
asthma, suggesting an independent determinant of
asthma severity [40]. Otherwise, there are few data about
the relative frequency of Trichophyton sensitisation in
asthma. One recent UK study found a frequency of 17%
in polysensitised severe asthmatics; 10% were sensitised
to Trichophyton as a single mould sensitisation, but only
2.5% were sensitized to Trichophyton alone [43].
What terminology can we use to capture the full
spectrum of disease characterized by fungal sensitization/
allergy, often associated with fungal airway infection?
ABPA/M has a well-established but restrictive definition,
leaving out the majority of patients sensitized to A. fumi-
gatus and related moulds without evidence of lung dam-
age. Perhaps ABPA, ABPM and SAFS are simply the
severe end of the same spectrum of disease. On the other
hand, sensitization to moulds is also seen in people with
mild asthma and good lung function or allergic rhinitis
where the mould may simply act as an allergen, although
it is possible that over time these people will develop fixed
airflow obstruction, bronchiectasis and even chronic pul-
monary aspergillosis and parenchymal fibrosis. Ideally,
definitions and inclusion criteria should be based on out-
comes, for example treatment response to antifungal
agents or risk of developing progressive lung damage.
However, there are virtually no robust data to guide this
approach. One simple option would be to adopt an inclusive
approach and relax the criteria for ABPA/M to describe any-
one with airway disease, evidence of allergy to thermotoler-
ant fungi (as defined by a positive serum sIgE or SPT) and
lung damage (fixed airflow obstruction, tree in bud shadow-
ing on CT scan, bronchiectasis of any description, or lung fi-
brosis). In this model, people with airway disease and
sensitisation to thermotolerant fungi, but no evidence of lung
damage, would be regarded as at risk of developing future
lung damage and kept under appropriate surveillance. If this
model were adopted it would need to be followed by large-
scale trials of antifungal and/or immunomodulatory agents
and large longitudinal cohort studies powered to relate the
various immunological and clinical features of ABPA/M
in its new definition to the risk of lung damage and the
benefits of eradication of airway fungal infection.
Disease concept research priorities
 Large longitudinal observational studies of people
with airway disease including asthma with different
severity and sensitization to A. fumigatus and other
fungi powered to determine the relationship between
development or progression of lung or airway
damage and the clinical and immunological criteria
currently used to define ABPA/M, SAFS and
sensitisation. Large studies of effective anti-fungal agents in people
with airway diseases including asthma of different
severity and sensitization to A. fumigatus and other
fungi powered to determine the relationship between
treatment outcomes, the course of disease and the
clinical and immunological criteria currently used to
define ABPA/M and SAFS.
Natural history and key findings
ABPA has a natural history that is both poorly character-
ized and difficult to predict, but better understood than
other entities of fungal allergy in asthma. ABPA does
not necessarily occur in the most severe cases of asthma.
Sensitization to fungi is rare in childhood, although
ABPA occurs occasionally in children [44-46], as does
the recently described SAFS. Sensitisation to Alternaria
in childhood (age 6 years) is associated with persistent
asthma in early adulthood [35], but no other fungal al-
lergens were tested. The natural history of fungal sensi-
tisation in mild or moderate asthma is not currently
described at all.
Patterson et al. described five non-sequential stages of
ABPA (acute, remission, exacerbation, steroid-dependent
asthma and fibrosis) based on clinical presentation, in-
cluding recurrent and/or chronic persistent symptoms
[47,48]. This staging, however, does not necessarily re-
flect the disease’s progression. Although the disease may
remit temporarily, it is more often a progressive disorder
with recurrent, infrequent acute episodes that cause suc-
cessive bronchial damage. Tissue damage tends to be
greatest in the proximal airway region, where mycelial
plugs and antigen production are localised, giving rise to
granulomatous airway inflammation that results in the
characteristic proximal bronchiectasis [49]. In the early
stages of ABPA, the bronchial wall is infiltrated with
mononuclear cells and eosinophils. If mucoid impaction
and atelectasis occur, they may be followed by bronchio-
litis obliterans, granulomatous bronchiolitis, and pul-
monary fibrosis [50].
A large variety of imaging changes are found in ABPA,
and may be related to the phase of the disease. Lung in-
filtrates, bronchiectasis and mucoid impaction are the
most common pathologic findings seen on a chest radio-
graph with ABPA. Transient changes include areas of
consolidation. The pathologic basis of consolidation is
unclear: it may be related to airway obstruction or eo-
sinophilia. Although such areas of consolidation are usu-
ally transient, some patients present with permanent
consolidation, perhaps due to endobronchial obstruc-
tion. When consolidation clears, it often leaves residual
bronchiectasis. The pulmonary findings of ABPA on
high-resolution CT (HRCT) include centrilobular nod-
ules, bronchiectasis (often with mucoid impaction), fi-
brosis and cavitation. In SAFS, only bronchiectasis is
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pleuroparenchymal fibrosis, a manifestation of chronic
pulmonary aspergillosis, is also described [51].
ABPA has been classified either in terms of ABPA-S
and ABPA-CB (depending on, respectively, the absence
(ABPA-S) or presence of bronchiectasis (ABPA-CB)) or
in terms of ABPA-S (mild), ABPA-CB (moderate) and
ABPA-CB-ORF (other radiologic findings) [52-54]. The
prevalence of bronchial dilatation in patients with severe
or persistent asthma ranges from 17% to 30%, compared
with 90% or more in ABPA [55]. It has been thought
that patients with ABPA-S represent the earliest stage of
the disorder, but prolonged follow up of this group
showed no interval development of bronchiectasis, des-
pite exacerbations [56]. In a study of 126 patients, the
clinical, spirometric and immunologic findings were not
significantly different when classified in terms of either
ABPA-S and ABPA-CB or ABPA-S, ABPA-CB and ABPA-
CB-ORF [57].
High-attenuation mucus (HAM) is a characteristic
radiologic finding seen in patients with ABPA [57], and
not in any other asthma entity. A multivariate analysis
showed that severity of bronchiectasis and presence of
hyperattenuating mucus impaction are predictive of
ABPA relapse, and that severity of bronchiectasis was an
independent predictor of failure to achieve long term re-
mission [58]. In the same study, HAM was shown to be
present in 18% of patients diagnosed with ABPA. Rea-
sons why hyperattenuating mucus is associated with
poorer outcomes remain unclear; high attenuated mucus
may be a more inspissated type of mucus. Perhaps this
subgroup of patients has more severe inflammation and/
or specific genetic alterations that favour the formation
of HAM [58]. More research is therefore required to in-
vestigate the exact reason for this association. It is not
clear whether bronchiectasis and pulmonary fibrosis
constitute sequels of mucoid impaction in ABPA. Mu-
coid impaction as an entity is not well understood, and
may be associated with Aspergillus bronchitis (usually
complicating bronchiectasis) and obstructing bronchial
aspergillosis (in immunocompromised patients).
The relapse frequency in ABPA is usually low, and re-
duced further by corticosteroid and antifungal therapy in
many patients. Whether significant external fungal expo-
sures precipitate relapse is not clear, but possible. Viral
and bacterial respiratory infections may contribute to re-
lapse, or to associated tissue damage and development
of complications. It may be that remission of ABPA and
SAFS occurs in older age, but this is not studied.
Pulmonary cavitation and fibrosis are often severe
complications of ABPA, and may occur in SAFS. In one
series, cavitation and atelectasis were shown to develop
in, respectively, 20% and 46% of patients with ABPA
[59]. Cavitation was observed to occur in patients with achronic infiltrate and was thought to represent necrosis
within an eosinophilic pneumonia. Cavitation may be re-
versible, following resolution of infection. The development
of chronic pumonary aspergillosis (CPA) with or with-
out cavitation may complicate ABPA and aspergillomas
have been reported in up to 7% of patients with ABPA.
Aspergilloma usually occurs in patients with longstand-
ing ABPA and extensive lung destruction, even though
this is not always the case: rapid formation of aspergil-
loma in early ABPA has also been described (before
bronchiectasis), implying that in some patients, it may
be formed from direct parenchymal invasion [60]. In a
recent study, ABPA was identified as an underlying con-
dition in 18 (14.3%) and, more specifically, as the pri-
mary underlying condition in 15 (11.9%) out of 126 CPA
cases, some with aspergillomas [51]. These findings sup-
port those from a study of aspergillomas where ABPA
was identified as an underlying condition in 11.8% (10
out of 85) of cases reviewed [51]. The fact that ABPA is
a relatively common underlying condition suggests that,
it is not so much the presence of Aspergillus itself, as
are the interaction of the lung’s condition (bronchiec-
tasis/fibrosis) and corticosteroid exposure (which is the
treatment of choice for ABPA) that are the risk factors
for development of CPA. The radiological manifesta-
tions of early CPA in ABPA are not well delineated.
Whether antifungal therapy arrests the progress of CPA
complicating ABPA is not clear, but our anecdotal ex-
perience suggests it does. SAFS has also been associated
with CPA, though infrequently [51].
Invasive aspergillosis complicating ABPA has also been
rarely described, the first time in 1975 [61].
Natural history research priorities
 Large longitudinal observational studies of people
with ABPA and SAFS, including detailed imaging,
from as early a stage as possible after recognition to
ascertain the relative frequency and associations with
the different complications.
 Detailed study of mucoid impaction and
hyper-attenuating mucus.
 Genetic and functional studies comparing patients
with and without complications of ABPA and SAFS,
including those with mild and severe bronchiectasis
and those with early and advanced CPA.
 A better understainding of co-morbidities and their
impact on natural history, is also required.
Epidemiology
Asthma prevalence and burden of fungal allergy in asthma
The Global Burden of Disease 2010 project estimated
that asthma was ranked 43rd globally for years life lost
[62], although 15th and 20th in Oceania and Eastern
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with an estimated 334 million people affected; 14th in
terms of years lived with disability [63]; and 28th in
terms of disability-adjusted life years [64]. An estimation
of the adult burden of asthma using an alternative mod-
eling approach based on the global initiative for asthma
(GINA) yielded a global burden of 197 millions [65].
Utilising the 5 estimates of ABPA period prevalence
(0.7-3.5%, median 2.5%) among referred patients to
secondary care from South Africa, Ireland, Saudi Arabia,
New Zealand and China there are 4.8 million adults with
ABPA complicating asthma [65]. This estimate could
be an overestimate because only a proportion of cases
is referred to secondary care, or an underestimate because
milder cases are not investigated in the community or
referred, or were investigated previously and discharged
back to the community.
Global or national SAFS prevalence estimates have not
been made. The more severe asthma is, the higher is the
frequency of Aspergillus and fungal sensitisation. Assum-
ing that the worse 10% of adult asthmatics are severe
and that fungal sensitisation has a minimum frequency
of 33% in these people, about 6.5 million would be ex-
pected to have SAFS, although there is some crossover
with ABPA patients who also have severe asthma [65]. It
is not known how much regional or ethnic variation
there is in SAFS prevalence.
Environmental exposure
Many recent studies describe mould-related respiratory
effects in asthma [66-68]. Studies in environmental medi-
cine have established a clear causal relationship in mould-
induced asthma. Furthermore, these studies indicate that
prevalence of adulthood asthma induced by moulds is in-
creasing. The fraction of adulthood asthma incidence at-
tributable to work is about 30% [69]. Adult-onset asthma
is strongly associated with the level of fungal exposure
[70]. Quite recently, moulds became the leading causative
factor for occupational asthma (OA); notably in Finland.
All de novo diagnosed cases of occupational asthma in
Finland are obligatorily reported to the National Register,
and by 2002 moulds become the most important causative
agent (18% of cases in 1998-2002) [71]. Importantly, diag-
nosis of mould-induced asthma was confirmed by the
allergen-specific challenge tests. The people affected are
mostly white-collar employees, a population not generally
considered as a risk group for OA. The same increasing
trends have been shown in UK [72]. One of the most well
established causes of occupational asthma associated with
fungal allergens is alpha amylase from Aspergillus oryzae
which is used as a additive in bakeries and can lead to
‘bakers asthma’ [73]. Alpha amylase has also been impli-
cated in case reports in causing allergic reactions to white
bread [74].Outdoor The data on the association between total fun-
gal spore counts, spores grouped by their division or in-
dividual spore taxa and hospitalizations or visits to
emergency departments due to asthma exacerbations are
inconsistent. Recently, the relative abundances of fungal
genera were evaluated using pyrosequencing approach
in outdoor air samples from an urban US area and esti-
mated relative abundance of fungi recognised to be aller-
genic from 2.8% to 10.7% of total fungal taxa [75].
Several studies did not find associations of outdoor fun-
gal spore counts and visits to emergency departments or
hospital admissions due to asthma exacerbations in
adults [76,77], although both studies did find these asso-
ciations in children. Fungal sensitisation was not investi-
gated in these studies. In contrast, some studies have
shown that sensitization to fungi per se is a risk factor
for admission to an intensive care unit with an acute at-
tack of asthma [78] and respiratory arrest [79]. Subjects
who had been admitted to the ICU with severe life-
threatening asthma were significantly more likely to have
one or more positive skin tests for fungal dry weather
spores (Alternaria alternaria, Cladosporium cladospor-
oides, Helminthosporium maydis, Epicoccum nigrum).
O’Halloren et al. found that subjects who had a respira-
tory arrest during the Alternaria aeroallergen season
were more likely to have a positive skin test to Alter-
naria than other subjects with asthma [79]. Delfino and
coworkers found associations between fungal spore con-
centrations, particularly Alternaria and Helminthospor-
ium, and increased asthma symptom scores, decreased
evening PEF and β-agonist inhaler use in adult asth-
matics sensitized to fungi [80]. Additionally sensitisation
to A. alternata in asthmatic subjects with grass pollen
sensitivity was found to predict susceptibility to
thunderstorm-associated asthma [81]. Children living in
rural environments are less likely to have asthma and
fungal sensitisation [82], whereas adults are more likely
to have ABPA, at least in India (47% vs. 66%, p = 0.007),
which may or may not reflect airborne exposure [83]. It
is likely however that these differences are not simply
about indoor or outdoor air exposures, as the mould ex-
posures in indoor air were higher in rural environments
(in France) [84], and non-allergic mechanisms of asthma
exacerbation were suggested.
Indoor Moulds are commonly present in houses; a
study evaluating the presence of different mould species
in more than 1000 houses in Northeast USA revealed
that Cladosporium spp is found in 85%, Penicillium, As-
pergillus and Alternaria respectively in 75%, 50% and
28% of homes [85]. Reported mould exposure and recent
water damage is associated with asthma symptoms and
bronchial hyperresponsiveness in adult asthmatics [86].
This observed effect was consistent among 38 study
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tized to Cladosporium. Sensitization to moulds is more
prevalent in subjects leaving in damp dwellings com-
pared to subjects living in dwellings without any sign of
building dampness (9.3% vs 3.9% [87]). Furthermore, liv-
ing in damp dwellings per se is associated with current
asthma, lower FEV1 [88] and higher PEF variability [87].
Subjects sensitized to moulds, particularly to Cladospor-
ium and Alternaria are at significantly higher risk of
current asthma if they reported mould exposure
[86,87,89]. Prevalence of current symptomatic asthma
and use of asthma medications increase significantly
with higher Alternaria alternata allergen levels indoor
[90]. One study has shown that severity of asthma corre-
lates significantly with measures of total dampness and
mould growth in the dwelling [91]. However, numerous
other studies were not able to confirm these findings.
Wood and coworkers [92] did not find association be-
tween indoor mould and positive skin tests for common
moulds. Several studies have shown no association be-
tween visible indoor moulds or airborne moulds and
bronchial hyperresponsiveness [93,94].Epidemiology research priorities
 Detailed and population based studies of the
prevalence and annual incidence of SAFS, fungal
sensitisation and ABPA/M, in adults and children.
 Improved and more geographically diverse exposure
studies relating the nature of exposures to asthma
and ABPA severity.
There is accumulating evidence that mould exposure
is associated with asthma, however no clear exposure-
effect relations have been established. The only population-
based incident case–control study providing such evidence
has shown increased risk of asthma in relation to sIgE
antibodies to A. fumigatus and C. herbarum [95]. Inter-
estingly, the majority of studies do not provide evidence
that increased prevalence of asthma associated with
often assumed exposure to moulds is caused by the
hypersensitivity to fungi. Furthermore, no consistent as-
sociations were found for the objective measures of
asthma severity and control. This is in part because of
inconsistency and inadequate validation of the measures
used to evaluate exposure and health effects. Therefore,
it currently remains impossible to set evidence-based
guidelines for avoidance of fungi. Perhaps colonization
or infection of the airways in affected people over-
shadows external fungal exposure, although a recent
study found A. fumigatus isolation from sputum to be
associated with elevated airborne levels in homes of pa-
tients with asthma [96].Pathogenesis
The pathogenesis of ABPA has been extensively studied,
unlike fungal sensitisation and associated asthma. Although
there is a correlation between the degree of exposure to
Aspergillus spores and the development of ABPA, many
findings suggest that ABPA is primarily the result of ab-
normal host immune response to Aspergillus antigens.
Given that high incidence rates of ABPA have been re-
ported in a number of families, such an abnormal host
response is probably influenced by genetic factors
[97,98]. While factors that allow growth of Aspergillus
in the airways of ABPA patients remain unclear, bron-
chial mucus abnormalities have been implicated. For ex-
ample, for unknown reasons, the mucus in ABPA can
become extremely viscid and difficult to remove [99].
Clearly, complex interactions between host susceptibil-
ity and fungal development in the local pulmonary en-
vironment occur and need to be deciphered.
Lung microbiota
The application of sequence-based identification and
metagenomics to studies of the human microbiome has
revealed a plethora of organisms that can inhabit the hu-
man body including new or as yet unknown pathogens
[100-102]. Most published studies have focused on bac-
terial communities, but fungi also form an important
component of the microbiome [103]. The internal tran-
scribed spacer regions (ITS1 and ITS2) of the nuclear
ribosomal operon are the most popular loci used to
identify and discriminate between fungal species and ref-
erence databases have been developed to allow compari-
son and identification of amplicons [104,105]. These
regions have been the target of the few published lung
fungal microbiota studies [104,106,107]. Unfortunately
none have addressed ABPA, although a massive number
of fungal species have been found in pooled sputum
samples from asthmatics [108]. One area of uncertainty
is the pathology of fungal growth within the lungs. Al-
though in florid cases hyphae can be seen in mucus and
there are old descriptions of bronchocentric granuloma-
tosis (a distinctive immunopathology of allergic fungal
disease), the extent and location of fungi in ABPA and
SAFS affected lungs have not been well described.
Whilst fungal components do not need to be viable to
elicit an allergic reaction, infection can only be caused
by viable fungal cells. Conventional DNA-based methods
for microbial identification are unable to differentiate
between viable and nonviable cells, often resulting in an
overestimation of microbial targets, which could be a
major limitation. One approach that may circumvent
this is viable-PCR (v-PCR), which utilises propidium
monoazide (PMA) to detect only viable cells [109]. V-
PCR has been applied to a number of microorganisms,
including fungi, and has been used in conjunction with a
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ation sequencing. In sputum samples from individuals
with cystic fibrosis, comparison of PMA treated and un-
treated clinical samples indicated that dead bacterial
cells significantly bias untreated profiles [110].
Although high-throughput technologies have facili-
tated the identification and characterization of the hu-
man microbiome at mucosal sites including lungs, the
mechanisms by which the commensal flora might influ-
ence lung immunity and their role in the development
of allergic inflammation are not well characterized. Lung
microbiota analysis is a new translational research area,
offering the potential to redefine the processes that
drives the progression of respiratory disease in asthma.
Such studies will clearly impact our patient manage-
ment, changing current paradigms of allergy/asthma and
therapy.
Host-pathogen interactions
Neglect or react? Every day we breath 20,000 times,
thereby inhaling ~10,000 liters of air, which during the
fungal season can often contain >50,000 fungal spores
per cubic meter of air per day [111]. The size of these
spores (approximately 2-50 μm) enables the smallest to
reach the distal airways. For immune homeostasis it is
critical to prevent excess inflammation and tissue dam-
age in response to harmless species [112,113]. In re-
sponse to the inhaled fungi, the pulmonary immune
system has to decide whether to:
(i) tolerate the presence of these fungi or
(ii) to initiate an anti-fungal host defense program.
This decision and the resulting downstream signal-
ing are critical for the integrity and maintenance
of pulmonary host defense. These immunological
‘neglect’ or ‘react’ checkpoints are of key relevance
for inhaled opportunistic fungi, in particular the fila-
mentous saprophytic A. fumigatus or commensals,
such as Candida species. These fungi can both
colonize and infect the airways not only upon sys-
temic immunosuppression, but also in pulmonary
diseases where the local mucosal host defense is com-
promised, such as allergic asthma and cystic fibrosis
[4,114-117]. Fungal colonization is the necessary ante-
cedent event for sensitisation in the pathogenesis of
ABPA, but it is unclear why only some individuals be-
come sensitised. The factors determining the timing of
sensitisation are not known and likely relate to a con-
current viral exposure and/or genetic predisposition
(see Figure 2).
React The pulmonary immune barrier function is
mainly achieved by the lining epithelial cells, alveolarmacrophages and pulmonary dendritic cells (DCs).
These innate immune cells, are the first sentinels to
recognize and react to inhaled fungi. Upon contact with
fungi, airway epithelial cells produce large amounts of
cytokines and chemokines, such as the prototypic inter-
leukin 8 (CXCL8), which recruit leukocytes to the pul-
monary site of infection to enhance antifungal host
defense activities. The outcome of this initial interaction
orchestrates the subsequent immune response. Macro-
phages phagocytose fungi, neutrophils phagocytose and/
or release their granule contents and form DNA neutro-
phil extracellular traps (NETs) to entangle, immobilize
and kill the fungus, a process involving neutrophil-
derived calprotectin [118,119]. Even NK cells were re-
cently found to potently fight Aspergillus fumigatus
[120]. However, some fungi are capable of evading these
host defense mechanisms, for instance Candida, by af-
fecting phagosome maturation and phagosomal escape
by formation of hyphae that destroy the vesicle and sub-
sequently the entire host cell [121,122]. Neutrophils play
the prime role in controlling A. fumigatus invasion and
are essential in restraining tissue invasion and fungal
spreading from the airways into the bloodstream
[123,124]. In case of the allergic airway response to As-
pergillus, the TH2-associated chemokine CCL17/TARC
plays a key role in both murine and human fungal
asthma [125,126]. CCL17 binds to CCR4 and thereby re-
cruits TH2 cells into the airways that, in turn, drive IgE
production and mast cell degranulation and feed the
pro-allergic/-asthmatic airway response. Furthermore,
CCL17 has been shown to impair macrophage killing of
Aspergillus [125]. Since CCR4 is also expressed on Treg
populations, these immunosuppressive cells may add-
itionally favor survival of the fungus and a shift towards
a TH2 response. Clinically, CCL17 may serve as a serum
biomarker in patients to differentiate sensitization to As-
pergillus from clinically active ABPA flares, especially
when quantified longitudinally, as supported by two
studies [127,128]; cutoffs are not established. Inspired by
findings in animal models of ABPA, anti-CCL17 anti-
bodies are currently being developed (Hogaboam CM,
personal communication).
Among cells of adaptive immune system, particularly
IL-17-secreting T-helper cells (Th17) play a key role in
anti-fungal host defense [129,130]. Autosomal recessive
IL-17RA and autosomal dominant IL-17F deficiencies
have been reported in chronic mucocutaneous candidia-
sis (CMC) patients [131]. A recent study further shows
that IL-17A itself is able to bind fungal cells, thereby
causing nutrient starvation conditions [132]. The Th17
response works in concert with IL-22, IL-23 and Th1/
Tregs responses to control fungal dissemination [133].
On the other hand, dysregulation of these pathways can
drive exaggerated inflammatory responses/hyperinflammation
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(CGD) in mice [134]. These studies also show that the
indoleamine 2,3-dioxygenase (IDO), a key enzyme of
tryptophan metabolism, is involved in CGD-associated
inflammation and tryptophan catabolites (kynurenines)
could be therapeutically useful to regulate and dampen
hyperinflammation [135,136] although the regulation of
this pathway in human CGD is different [137-140].
How are fungi recognized? Similar to other microbes,
fungi are recognized through conserved pattern recogni-
tion receptors (PRRs) of the innate immune system.
Two families of PRRs are essential in fungal recognition:
 C-type lectin receptors (CLRs) and
 Toll-like receptors (TLRs) [118].
Prototypic CLRs include dectin-1, complement recep-
tors, and macrophage mannose receptor. Less well-
described include DC-SIGN, dectin-2 (recognizing
house-dust mite), DCL-1, Mincle and CLEC5a. These
CLR receptors have in common that they are coupled to
Syk, which enables signaling via CARD9 and subsequent
NFκB downstream activation [141]. Activation of these
receptors by whole fungi through a proposed ‘phagocytic
synapse’ [142] or fungal components (prototypically ß-
glucans) elicit anti-fungal effector activities, that are
(opsono)phagocytosis, cytokine production and respira-
tory burst. A recent study highlights that the interaction
of Aspergillus conidia with the key CLR dectin-1 in the
lung mainly takes places intracellularly in acidified pha-
golysosomes, following the phagocytosis of fungi by leu-
kocytes [143]. The pathophysiological and clinical
disease relevance of these receptors is corroborated by
the finding that genetic mutations in distinct CLRs,
namely dectin-1 [144] and CARD9 [145], cause CMC and
other fungal infections. Beyond these pathways, STAT1
mutations have also been associated with CMC [146].
While genetic inheritance for susceptibility to Candida
has been established, the molecular genetic basis for As-
pergillus infections in humans remains to be defined.
In addition to CLRs, TLRs also recognize fungal pat-
terns. The MyD88-coupled TLRs TLR1, TLR2, TLR4,
TLR6 and TLR9 have been reported to contribute to
fungal recognition in different experimental systems,
with TLR2, TLR4 and TLR6 probably being the most im-
portant ones [147-150]. Cellular studies are supported
by genetic association studies showing that one TLR4
polymorphism is weakly linked to susceptibility for inva-
sive aspergillosis following haematopoetic stem-cell
transplantation [151,152]. Studies with genetic knock-
out mice mainly support the role of TLR2 and TLR4 in
fungal recognition, but the specific receptor utilized de-
pends on the phenotype of the fungus (stage-specificrecognition, conidial vs. hyphal) and on the host genetic
background (Brown GD, personal communication).
Besides cellular receptors, fungal patterns are recog-
nized both by soluble innate immune receptors. Collec-
tins, such as surfactant protein A (SP-A), SP-D, galectin-3,
pentraxin-3, mannose binding lectin (MBL), C-reactive
protein, complement, ficolins and others are in vivo the
first proteins to bind fungi and facilitate the uptake and
clearance by surrounding phagocytes. A recent study
shows that opsonisation with surfactant components in
the lung limits inflammation by attenuating host-fungi in-
teractions, a mechanism relevant for zymosan but not for
Aspergillus species [143], underscoring the complexity of
host-fungus interactions in the lung.
Pathogenesis research priorities
 Define the lower respiratory tract microbiome in
ABPA, SAFS, ABPM and in asthmatics sensitised to
different fungi, combined with v-PCR and other
measures of microbial viability.
 Study specific fungal factors and host components
that are worth targeting in patients, in order to (i)
improve clearance of the pathogen and to (ii) limit
hyperinflammation-mediated tissue damage.
 The mechanisms of airway and lung damage in
ABPA and SAFS. The impact of treatments,
including corticosteroids, on those mechanisms.
 Studies of the immunological response to fungi to
determine the relationship between TH2 allergic
responses and Th1/Th17 infection related responses.
Genetic associations
Several small studies have identified certain genetic fac-
tors linking the risk of ABPA with individual mutations.
Multiple associations are to be expected given a family
history in 5% of those with ABPA [98]. The genes impli-
cated to date include IL-4Rα [153,154], IL-10 [155], sur-
factant A2 (SPA2) [156], TLR9 [30], CFTR [157-159],
and HLA DR2/DR5 polymorphisms [160]. Some of these
associations are not strong, and some may be related to
disease progression or complications, rather than being
risk alleles per se. All studies to date are relatively small.
No genetic associations have been described with SAFS
or other fungal allergic conditions.
Genetic association/risk research priorities
 Expand confirm and evaluate the number of genetic
associations with ABPA and other fungal allergic
conditions, compared with asthmatic patients
without these fungal disorders.
 Define genetic pathways that regulate the
susceptibility towards and damage response
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functional studies comparing patients with and
without complications of ABPA and SAFS, including
those with mild and severe bronchiectasis and those
with early and advanced CPA.
 Risk associations in patients with and without
disease could be direct associations with disease or
indirectly related to complications such as
bronchiectasis or worse pulmonary function. Thus
association studies should include well documented
complication rates and functional status over time.
Diagnosis and screening
A definitive diagnosis of the following 8 features to be
present as follows: asthma; immediate Aspergillus skin
prick test positivity (sensitivity and specificity: 94.7%,
79.7%); IgE levels >1,000 IU/mL (97.1%, 37.7%); positive
A. fumigatus specific IgE (no value specified or studied)
(100%, 69.3%); Aspergillus precipitins detectable (42.7%,
97.1%); eosinophil count >1,000 cells/uL (29.5%, 93.1%);
transient or fixed chest radiographic opacities (36.1%,
92.5%); (central) bronchiectasis (91.9%, 80.9%); and high-
attenuation mucus (39.7%, 100%) [5] (Table 2). So a key
question is how these criteria should be applied in the
routine clinical setting. Which are most useful as screen-
ing criteria to identify all those with ABPA? Further, can
the same screening test(s) be used to identify patients
with SAFS, also deserving of a trial of antifungal ther-
apy? These questions have recently been addressed by
an International Society for Human and Animal Mycol-
ogy (ISHAM) working group report which proposed
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then be performed to establish the diagnosis of ABPA.
What arguments are in favor of this approach, or another?
Performance variability in the screening tests used to
identify ABPA, SAFS, and those sensitised to fungi are
pivotal to diagnosis, estimates of prevalence and under-
standing pathogenesis.
The skin-prick test (SPT) is a simple diagnostic tool
that can be useful for screening for ABPA [161], but it is
not without limitations. The accuracy and reliability of
the SPT and other in vivo and in vitro assays is highly
dependent on the quality of the fungal extracts used.
The quality can vary dramatically between commercial
suppliers, which can be caused by inconsistencies in the
preparation of fungal extracts; for example, using either
fungal mycelia or spores for production. Inter-strain
variability leads to extracts with altered protein compos-
ition, resulting in poorly standardised allergy testing so-
lutions [162]. The majority of SPT positive individuals
are also positive by specific IgE, giving the SPT a high
negative predictive value (95%); however a significant
proportion of individuals with positive IgE tests are SPT
negative [4]. Intradermal tests are more sensitive than
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ment of multiple specific IgE antibodies may be more
costly than SPTs. The CAP system for specific serum
IgE testing has higher sensitivity than RAST tests with
comparable specificity; and a recent study has suggested
that both SPTs and specific IgE measurement by the
(ImmunoCAP) system should be used in diagnoses of
fungal allergy, due to discordance in test results in
around a quarter of severe asthma patients [43]. Specific
recombinant allergen testing may play a greater role in
diagnosing ABPA in the future. Specific A. fumigatus al-
lergens have been evaluated for their diagnostic per-
formance in serologic studies in asthmatic patients
[164], and data suggests they may be useful in discrimin-
ating between ABPA (Asp f 2, Asp f 4 and Asp f 6) and
fungal allergy (Asp f 1 and Asp f 3) [165,166]. Aspergil-
lus precipitating antibody is found in <50% of ABPA pa-
tients and fewer SAFS patients, and is therefore a poor
screening tool. Likewise radiology is insensitive and non-
specific enough in ABPA and wholly unsatisfactory for
screening for SAFS, in which radiology is often normal
or nearly so.
Classic ABPA cases in the absence of oral corticoste-
roids have peripheral blood eosinophilia [167]; however,
this feature may be only present at the time of exacerba-
tion or during the acute phase of the disease [168]. A
peripheral blood eosinophil count of above 1,000 cells/ul
is often cited as a secondary diagnostic criterion and
whilst it is still considered to be suggestive of ABPA [4]
the utility of it as a diagnostic tool has been questioned
[20,168], as most patients with ABPA have fewer eosino-
phils than this on presentation. One study to address
this found no correlation between peripheral blood eo-
sinophil levels and lung function or other immunological
parameters; and whilst prevalence of central bronchiec-
tasis was higher in patients with higher eosinophil
counts, the severity of bronchiectasis did not correlate
with the degree of peripheral eosinophilia [20]. Consen-
sus of 500 cells/ul (at presentation or previously) was
reached by the ISHAM working group, and needs pro-
spective validation.
Culture of A. fumigatus from sputum is supportive but
not diagnostic of ABPA, as the fungus can also be cul-
tured from patients with other pulmonary diseases
[169]. Sputum samples from individuals with asthma are
usually culture negative [24]. The standard approach
used to process sputum for mycological investigations in
the UK has been shown to potentially underestimate
fungal prevalence in the airway [170], and a recent
multi-centre study has highlighted the variability in cul-
ture results that arise from different mycological
methods being employed [171]. As such a number of
groups have questioned the performance of the current
UK respiratory culture methods for fungi and have calledout for an improved, standardised approach [170-173].
PCR has been proposed as an alternative or additional ap-
proach to detecting Aspergillus species in sputum and has
been shown to be more sensitive than culture in ABPA
but needs to be interpreted with other clinical and labora-
tory features [174]. DNA-derived signals can originate
from nonviable fungal cells [175,176] and therefore there
is the potential for a positive PCR signal to derive from
dead fungal material, particularly in the context of a pa-
tient who has been treated with antifungals.
Diagnosis and screening research priorities
 Develop more standardized skin test and blood test
reagents for detecting fungal sensitization, with
validation in different populations with other
potential causes of elevated IgE, such as chronic
helminth infection.
 Assess the performance of better standardized tests
for detecting ABPA and SAFS in asthmatics seen in
routine clinical practice.
 Compare the performance of simpler combinations of
tests to diagnose ABPA and SAFS, not including
complications as a component of the diagnostic
definition.
To summarise, the current tests used to determine
fungal sensitisation are not without limitations, and the
discordance between test results must be taken into con-
sideration. The use of specific recombinant allergens to
discriminate between ABPA and fungal allergy has
shown great potential and may be of importance in the
future. The detection of A. fumigatus and other fungi
from clinical specimens such as sputum is highly
dependent upon the methodology used, and a more sen-
sitive approach that is standardised and universally
adopted is a definite need.
Clinical management
There are 5 aspects to the management of fungal allergy
in asthma. These are:
1. Avoidance of fungi
2. Control of the inflammatory process
3. Improvement of airway air flow through reduction
of mucus and obstruction
4. Reduction of fungal burden
5. Control of bacterial infection
Decreasing indoor exposure to moulds
Allergen avoidance remains the cornerstone in the man-
agement of any allergic condition. Several interventional
studies employing remediation of damp buildings [177],
removing visible mould [178], removing water damaged
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alterations to heating [182], improving ventilation [178]
and fixing buildings construction to prevent further
water leakage [183] have been conducted. The interven-
tions were conducted either at home [178,182,183] or in
the working place [179-181,184,185].
Studies performed in occupational settings have shown
that employees more commonly report improvement of
symptoms while being away from work [179] and indi-
cated a reduction of respiratory symptoms including
cough, shortness of breath, wheezing [185], stuffy or
runny nose, eye, throat, skin, and headache symptoms
[179] after evacuation/relocation from the infected
building [179,185]. In active intervention studies patients
in remediation groups reported significant reduction of
bronchitis [180], improvement in wheeze affected activ-
ities, perceived reduction in asthma medications (both
relievers and controllers), symptoms of rhinitis [178] in-
cluding allergic rhinitis [180], conjunctivitis [180,184],
rhinoconjunctivitis [178], complaints on irritated eyes or
nose and skin rash [181]. When remediation is com-
pared to no remediation, a significant decrease in re-
ported wheezing [178,183], need for asthma relievers
and controllers [178] and trend toward fewer hospital
admissions for respiratory conditions [183] in those pa-
tients whose homes or work places had remediation
undertaken. However, other studies failed to show a
beneficial effect of intervention [182,184,186]. Inconsist-
ent effects of remediation on lung function are also
noted [178,180,181].
Farm environments could represent an occupational
risk, as reported from India [83]. Specifically poultry farms
may represent a local major source of fungi [187,188] and
poultry workers have a higher rate of asthma [189,190]
and mould IgG antibodies [189]. Protection of these
workers may be important, but is not studied.
Numerous caveats accompany these interventional stud-
ies and they have several limitations. Interventions are ap-
plied indirectly to a particular participant as it the building
is usually that receives attention. Moreover, usually it was
impossible to determine a separate effect of mould reduc-
tion from interventions themselves such as increasing in-
door temperature toward normal level could influence
health. Some ‘common sense’ avoidance measures are usu-
ally recommended to affected patients such as avoidance of
all composting, changing pillows regularly, avoiding build-
ing works, especially of old buildings, cellars and loft
spaces. The evidence for these avoidance measures is lim-
ited [191]. Currently, additional studies are required to es-
tablish evidence-based guidelines on mould avoidance.
Control of the inflammatory process
Inhaled corticosteroids have transformed the manage-
ment of asthma. Regular use in symptomatic asthmaticsreduces mortality, but their impact in those with min-
imal or intermittent symptoms is not clear and they may
be detrimental. One small prospective multicentre ran-
domized controlled trial (RCT) in ABPA comparing
beclomethasone and placebo showed no overt benefit
and an increase in the frequency of Aspergillus isolation
from sputum in the active group [192]. Despite beclo-
methasone, seven patients had clinical exacerbations as
well as more radiological exacerbations than placebo. A
23 patient study of ABPA patients without bronchiectasis
treated with inhaled corticosteroids showed subjective im-
provement but without complete control of asthma and
median IgE levels increased [193]. The impact of inhaled
steroids on ABPA (as opposed to asthma) is unclear and
may only be necessary to improve asthma control. Inhaled
corticosteroids are insufficient alone in controlling ABPA
or fungal colonization, and could be detrimental in the lat-
ter, but this is unstudied.
There are no RCTs trials of systemic corticosteroids in
ABPA although they are generally accepted as appropri-
ate therapy for acute exacerbations. However few data
are available to guide either dose or duration of cortico-
steroids. Lower doses of corticosteroids without antifun-
gal therapy (0.5 mg/kg/day for 1-2 weeks, then on
alternate days for 6-8 weeks then taper and discontinue)
is associated with 45% more relapse and subsequent oral
corticosteroid dependence [167]. A higher dosage of cor-
ticosteroid for longer (0.75 mg/kg for 6 weeks, 0.5 mg/
kg for 6 weeks, then tapered by 5 mg every 6 weeks to
continue for a total at least 6 weeks) was associated with
a higher remission rate and a lower prevalence of
corticosteroid-dependent ABPA (13.5%) [57]. Parenteral
steroids may be required for ABPA unresponsive to oral
steroids and antifungals, and may down-regulate steroid
receptors [194]. Whether the benefit of short-term con-
trol with oral corticosteroids correlates with longer-term
outcome has not been assessed. A RCT on the efficacy
and safety of two different glucocorticoid dose regimens
in ABPA (clinical trials.gov; NCT00974766) has been
completed and results awaited.
Omalizumab has an established place in the manage-
ment of some patients with severe asthma. Omalizumab
reduces symptoms, exacerbations, asthma hospitalizations
and has a steroid-sparing effect. While a recent study indi-
cates that omalizumab is associated with improvements in
outcomes in patients with uncontrolled persistent allergic
asthma [195], the very high IgE in ABPA makes the use of
omaluzimab difficult because of cost and administration
limitations (volume). Whether those patients with SAFS
should be first trialed on antifungal therapy or omaluzi-
mab or given both is not known.
Macrolide therapy (especially azithromycin) has an
anti-inflammatory role in some patients to decrease
cough and sputum production. This unexpected role
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patients with diffuse panbronchiolitis mainly found in
people from East Asia [196]. It has been used in those
with bronchiectasis, especially those with frequent exac-
erbations [197], as well as for other pulmonary diseases
[198]. It has not been studied in ABPA and in particular
the relative efficacy of macrolide versus itraconazole, in
patients with and without bronchiectasis is lacking.
Improvement of airway air flow through reduction of
mucus and obstruction
Nebulized hypertonic saline (6-7%, 4-5 mL) can be used
to reduce the viscosity of sputum to ease expectoration
of mucus plugs encountered in ABPA [199]. As hyper-
tonic saline can also induce bronchoconstriction [200],
caution is required with its initial administration espe-
cially in those with a low FEV1. Its role in ABPA has not
been actively addressed.
Mucus plugging of the airway is a characteristic fea-
ture of ABPA. Mucus is usually hypoattenuated, but may
be hyperattenuated on CT scan. The removal of mucus
plugs will generally improve clinical status and lung
function. Indeed mucoid impaction is one uncommon
presentation of ABPA. A course of oral steroids can
sometimes relieve obstruction. The role of either nebu-
lised hypertonic saline or N-acetyl cysteine in contribut-
ing to mucus plug removal is not studied. Therapeutic
bronchoscopy (flexible or rigid) is often used but its effi-
cacy and medium term impact is not studied or de-
scribed. Hyperattenuated mucus plugging may be more
difficult to relieve and is prone to relapse [58], and the
most effective means of removal of hyperattenuated
mucus and preventing relapse is not known.
Reduction of the fungal burden
Ketoconazole and inhaled natamycin were unsuccessful
therapies for ABPA and have not been attempted for
SAFS. There are no published data about nebulised
amphotericin B for either ABPA or SAFS. Itraconazole
was the first orally active agent against Aspergillus spe-
cies and many other filamentous fungi. Two randomized
placebo-controlled studies which enrolled a total of 84
patients both demonstrated benefit compared with pla-
cebo [201,202]. However the outcome parameters used
in the studies were different and were composite in the
first study. Pooled analysis showed that itraconazole re-
duced IgE levels by >25% when compared to placebo
but did not significantly improve lung function. In the
earlier, slightly larger study, the overall response rate was
60%, with a number needed to treat (NNT) of 3.58, con-
sistent with a very effective intervention. Patients with
ABPA may have continuing symptoms (asthma, bronchi-
ectasis) as well as acute exacerbations. These were not
separated out in terms of responses. Our own extensiveexperience is consistent with a range of responses, from
dramatic through minor improvement to a complete
lack of effect; the reasons for this response heterogeneity,
despite adequate drug concentrations in blood, is unclear.
Relapse after conclusion of active therapy was not re-
ported in either study. The frequency of acute exacerba-
tions is not well known in ABPA, although was infrequent
(16 of 41 (39%) over a mean period of 43 months) in a
group of patients without bronchiectasis [193].
Fluconazole and itraconazole are suggested as possible
effective treatments in the Tricophyton asthma [203], a
phenotype of uncertain frequency. Fluconazole was ef-
fective in improving asthma in a small RCT in moder-
ately severe asthmatics sensitized to Trichophyton, many
with cutaneous fungal infection [204]. This has never
been followed up. The use of terbinafine, which is active
against Trichophyton spp., is only anecdotal [205]. The
relative efficacy of fluconazole in those with multiple
fungal sensitisation is not known, and is predicted to be
inferior to itraconazole as it has a much more narrow
spectrum of activity.
A broader approach was subsequently trialled using
the wider spectrum agent itraconazole in SAFS patients
sensitized to one or more of 7 fungi [27]. Compared to
placebo, those treated with itraconazole over 8 months
had a significant benefit in the primary endpoint of qual-
ity of life, as well as a fall in total IgE and marginal im-
provements in morning peak expiratory flow rate. The
study was small (58 patients) and the confidence inter-
vals just overlapped, so a replication study is warranted.
Other data suggested a similar effect, but with some dif-
ferent parameters of response including reduced periph-
eral eosinophilia and improved FEV1 [206]. As with
ABPA, our clinical experience suggestes some dramatic
responses and some failures, with no clear cut reason
discerbable for the variable response. While the effect
size was similar to that seen in ABPA (NNT 3.22), the
place of itraconazole in the management of severe
asthma is not yet well defined.
The newer triazoles voriconazole and posaconazole
have been effective in some patients with ABPA and
SAFS, primarily in cystic fibrosis, but latterly in asthma
[29]. Most experience to date has been in those intoler-
ant to itraconazole or in itraconazole failures. Two re-
markable findings in this retrospective review however
were: (1) the large numbers of patients who were able to
come off oral corticosteroids and substantially reduce
their corticosteroid burden, and (2) that a third of the
patients had their asthma severity downgraded from se-
vere to moderate. These findings suggest a powerful im-
pact in a proportion of ABPA and SAFS patients, which
requires additional study (such as ATCF study, which is
underway and aims to evaluate the rates of converting
sputum cultures for Aspergillus from positive to negative,
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controlled clinical trial of CF patients). Unfortunately, the
recently published EVITA3 study failed to show improve-
ment in quality of life or the number of severe exacerba-
tions during 9 months after termination of a 3 months’
course of voriconazole in refractory asthma associated
with sensitization to A. fumigatus [207]. Voriconazole
200 mg bd was given for only three months and while
there was a significant reduction in the degree of A. fumi-
gatus colonization in the voriconazole group the drug did
not eradicate the mould from the sputum during the
treatment period and rates of positive culture returned to
baseline within a few months of stopping treatment. The
placebo group had a surprisingly good improvement rate,
and quality of life is often adversely affected by voricona-
zole, because of side effects.
As the bioavailability of itraconazole is variable and in-
adequate exposure is associated with higher clinical fail-
ure rates, therapeutic monitoring is required and is often
not done or available. Variable absorption from different
formulations of itraconazole contributes to the difficul-
ties of maintaining consistent exposure and therefore ef-
fect. The penetration of itraconazole, voriconazole and
posaconazole into sputum and extracellular lung fluid
(ELF) is variable and often low, despite adequate serum
concentrations, for unclear reasons [208]. Voriconazole
administered IV yielded high mean ELF concentrations
(range 10.1-48.3 mg/L) and a high penetration ratio
(7.1). In contrast, mean ELF concentrations of oral itra-
conazole and posaconazole were 0.2-1.9 mg/L, and the
ELF penetration ratios were <1 [209]. However both
itraconazole and posaconazole are concentrated inside
alveolar cells.
The optimum usage of itraconazole and other oral
azoles for therapy in ABPA is unclear presently, despite
the 2 RCTs described above. Monotherapy of itracona-
zole in ABPA is possible but not studied. A randomized
controlled trial comparing monotherapy of itraconazole
versus prednisolone in ABPA (MIPA study; clinical tri-
als.gov; NCT01321827) is underway, which aims to an-
swer this question. The duration of therapy and
frequency of relapse is unclear in ABPA, partly because
exacerbation rates are infrequent. Reversion to pre-
therapy status within 4 months was almost universal in
SAFS patients who discontinued itraconazole therapy
[27]. A recent study examining the impact of itracona-
zole on Vitamin D receptor expression in CF patients
suggests a prolonged effect of down-regulation, lasting
significantly longer than itraconazole therapy, possibly
indicating that after successful therapy a sustained effect
may be found in some patients [210].
The negative effects of itraconazole and possibly other
azoles, other than their own direct toxicities, include a
marked reduction in inhaled corticosteroid metabolism(with corresponding boosting of exposure) and azole re-
sistance in A. fumigatus [211,212]. In a UK study, pro-
found boosting of systemic corticosteroid exposure with
inhaled corticosteroids was seen in 50% of patients
treated with itraconazole, which reversed after 8 months
[27]. Interactions between both budesonide and flutica-
sone and itraconazole are documented, and are likely
with voriconazole and posaconazole, although may be
less marked. Ciclosonide and beclometasone do not ap-
pear to interact with azoles. Adrenal failure is however
described, typically after months or years of dual
therapy.
Control of bacterial infection
A high frequency of respiratory bacterial infections is
common in many of these patients. Most are presumed
rather than documented, but bronchitis attributable to
Streptococcus pneumoniae and Haemophilus influenzae
is common, especially in those with bronchiectasis [213].
Long-term administration of azithromycin or doxycyc-
line can alleviate some of these infections. Low specific
antibodies to these bacteria are common in these pa-
tients and occasionally this is the presentation of hypo-
gammaglobulinaemia. Immunisation with Pneumovax or
Prevnar 13 to prevent S. pneumoniae infection and
Menitorix to prevent H. influenzae is often done, but
not well studied [214-217]. Individual immunisation re-
sponses are highly variable, and often poor to Pneumo-
vax. Reduction of exacerbations and recurrent infection
has a major benefit for patients, and reduces corticoster-
oid courses.
Treatment and general management research priorities
 Additional studies on avoidance strategies to prevent
fungal sensitisation in established asthma and
course/exacerbations of fungi-related asthma and
conditions related to incidental fungal exposures.
 The mechanism of benefit of antifungal therapy
needs clarification, with development of biomarkers
for response assessment.
 RCTs of voriconazole, posaconazole, isavuconazole
and nebulized amphotericin B need to be conducted
in ABPA and SAFS.
 Studies on antifungal and anti-IgE treatments in
SAFS.
 The role of adjunctive therapies such as macrolide,
antibiotic prophylaxis, mucus reduction, the efficacy
and impact of anti-Pseudomonas therapy needs to be
assessed.
 The avoidance and management of azole/corticosteroid
drug: drug interactions needs addressing.
 The dual interaction of antifungal development of
azole resistance and/or acquisition of a resistant strain
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increasing frequency of azole resistance in A.
fumigatus.
 The optimal means and impact of reducing
amplification of inflammation, through prevention of
bacterial and viral intercurrent infection.
Some patients become infected and others colonised
by Pseudomonas aeruginosa, usually those with bronchi-
ectasis [218]. Strategies to eradicate this with intraven-
ous, dual antibiotic therapy are commonly used, without
any clinical trial basis. The standard registered doses of
ciprofloxacin are inadequate for most patients [219,220]
and high doses such as 500-750 mg three times daily are
more efficient. Newer approaches include oral high dose
ciprofloxacin combined with nebulized colistin, follow-
ing the lead of the cystic fibrosis community [221]. Data
are lacking on impact and efficacy.
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